Testing treprostinil safety in children with PAH
Part of Lungs & breathing clinical trials.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have severe pulmonary arterial hypertension (PAH) and need treatment with a prostacyclin drug given through an IV or under the skin.
- PAH diagnosis must be confirmed by a right heart catheterization or, in very young children, by an echocardiogram.
- Your child must not be allergic to prostacyclin-like medicines.
- Your child cannot have uncorrected heart defects that need surgery in the next 5 months.
- Your child must not have any significant lung disease.
- Girls who can become pregnant must use two reliable forms of birth control and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This study provides continued access to an investigational inhaled medicine (treprostinil palmitil inhalation powder) for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already been in earlier studies of this treatment. It allows you to keep receiving the treatment under medical supervision.
This study is testing how safe and effective Remodulin is for people with severe pulmonary arterial hypertension (PAH). You will receive Remodulin as a continuous injection under the skin or into a vein, and the study will monitor your health to see how well it works.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.